Introduction {#j_jomb-2017-0016_s_003}
============

Glycated hemoglobin (HbA1c) is a well-established indicator of mean glycemia. HbA1c is the result of irreversible glycation of the N-terminal amino acid (valine) of the HbA0 β-chain ([@j_jomb-2017-0016_ref_001]). Glycation of the amino group of the N-terminal residue produces a loss of a positive charge, which is the basis for methods that quantitate HbA1c by ion-exchange chromatography ([@j_jomb-2017-0016_ref_002], [@j_jomb-2017-0016_ref_003]). However, the presence of Hb variants may falsely produce low values for HbA1c or spuriously increased HbA1c values. Hemoglobinopathies can affect HbA1c values in 3 ways: by influencing the binding of glucose to Hb, affecting chromatography peak measurements, and increasing the risk of hemolysis and hence decreasing the life span of red blood cells ([@j_jomb-2017-0016_ref_004]). Hb G-Coushatta (HBB:c.68A\>C) is a β-globin variant in which an alanyl residue occurred in place of the glutamyl group at position 22. It was first described in an American Coushatta Indian family ([@j_jomb-2017-0016_ref_005]). Hb G-Coushatta elute in the Hb A~2~ window and could be mistaken for the common variants like Hb E and Hb D-Iran which also elute in the same window on HPLC ([@j_jomb-2017-0016_ref_006]). It was emphasized in the literature that Hb G-Coushatta causes an interference in HbA1c measurement by the ion-exchange HPLC method ([@j_jomb-2017-0016_ref_007]). We found that whereas this interference is very prominent in homozygote Hb G-Coushatta cases, it can be easily missed in heterozygote Hb G-Coushatta cases when unattended.

Results {#j_jomb-2017-0016_s_004}
=======

Hematological tests were done in a 45 years old female non-diabetic patient suffering from anemic symptoms. Complete blood count, serum ferritin, fasting glucose, HbA1c and hemoglobin chromatogram analysis were done respectively on a Coulter LH 780 Analyzer (Beckman Coulter, Holliston, MA), DXI 800 Analyzer (Beckman Coulter, Holliston, MA), AU5800 Analyzer (Beckman Coulter, Holliston, MA), by an ion-exchange HPLC method in a HLC-723G7 Analyzer (Tosoh Bioscience, San Francisco, CA), and by HPLC using the short program for the Variant II (Bio Rad, Hercules, CA).

The results of tests were: RBC: 4.42 10^12^/L, Hb: 126 g/L, Hct: 37.1%, MCV: 83.7 f/L and ferritin: 4.6 ng/mL. Treatment for iron deficiency anemia was planned according to these results. Fasting glucose was 5.0 mmol/L and HbA1c was 2.9% (reference range: 4--6%).

Since HbA1c level was very low compared to reference range, measurement was repeated by an immunoturbidimetric assay method (Dimension RxL Max, Siemens, Malvern, PA). Actual HbA1c level was 5.6% (reference range: 4.3--6%) by this method. When we compared the results of the two methods, we determined that the HPLC method measured an HbA1c level 45% lower than the immunoturbidimetric assay method leading to an interference. Hemoglobin variant analysis of the patients showed an abnormal pattern (HbA0: 4.9%, HbA2: 78.3% and HbF: 0.4%). A peak of 78.3% HbA2 and low value of HbA1c (2.9%) alerted us to a possible presence of hemoglobinopathy (*[Figure 1](#j_jomb-2017-0016_fig_001){ref-type="fig"}*). DNA sequencing showed a b chain variant homozygote Hb G-Coushatta (HBB: c.68A\>C). Thirty-seven years old sister of the patient was also screened for β-thalassemia by HPLC. Analysis showed a peak of 40.7% in the HbA2 window (HbA0: 45.8%, HbA2: 40.7% and HbF: 0.1%) (*[Figure 1](#j_jomb-2017-0016_fig_001){ref-type="fig"}*). On DNA sequencing, this variant was identified as heterozygote Hb G-Coushatta (HBB: c.68A\>C). Ion-exchange HPLC method revealed 4% of HbA1c, which is in the normal range (4--6%). But, we determined the actual HbA1c level as 5.3% by an immunoturbidimetric assay. These results showed that the heterozygote Hb G-Coushatta variant causes 20% of interference by the ion-exchange HPLC method in HbA1c measurement.

![Ion-exchange HPLC chromatogram for HbA1c and Hb variants analysis of patients with Hb G-Coushatta.](jomb-36-270-g001){#j_jomb-2017-0016_fig_001}

Hb G-Coushatta is found in geographically separated ethnic groups. It has been reported in many countries including Algeria, Japan, Korea, Thailand, Egypt, China, Sri Lanka and Turkey ([@j_jomb-2017-0016_ref_008]). Hb G-Coushatta variant is the most common variant in Korea and the Silk Road region of China ([@j_jomb-2017-0016_ref_009]). Although the real prevalence of Hb G-Coushatta variant is unknown in Turkey ([@j_jomb-2017-0016_ref_010]), it is likely that the global prevalence is underestimated because Hb G-Coushatta is asymptomatic. This variant usually leads to underestimation of HbA1c ([@j_jomb-2017-0016_ref_011], [@j_jomb-2017-0016_ref_012]) as we noted in our patients. We found that the HbA1c level measured by an ion-exchange HPLC method was very low compared to reference range in the patient with a homozygote variant. Therefore, it is much more easy to think possible hemoglobinopathy in homozygote variants. But, we found the HbA1c level normal by an ion-exchange HPLC method in the heterozygote case.

If Hb G-Coushatta was not searched for particularly, the HbA1c level would be accepted as normal leading to misdiagnosis of possible diabetes mellitus in this heterozygote case in the future. In conclusion, Hb G-Coushatta interferes with the quantitation of HbA1c. Particularly in heterozygote Hb G-Coushatta cases, HbA1c levels measured by HPLC are reduced to 20% less the actual level. So, in places where the Hb G-Coushatta variant is common, although HbA1c measured by an HPLC ion-exchange method is in the normal range, heterozygote variants must be excluded by hemoglobin variant analysis.
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